Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer
The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.
1. A method of treating colon cancer in a mammal,
wherein the method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I):
wherein:
R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted heterocyclylalkyl, optionally substituted heteroarylalkyl, —C(O)R 6 , —C(O)N(R 6 )R 7 , —S(O) t R 6 (where t is 1 or 2), —S(O) 2 N(R 6 )R 7 , —P(O) z OR 6 and —C(S)R 6 ;
R 3 and R 4 are independently selected from the group consisting of hydrogen, alkyl, optionally substituted aralkyl, —C(O)R 6 , and —C(O)OR 6 , or R 3 and R 4 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl;
R 5 is selected from the group consisting of —C(R 9 )═C(R 9 )—[C(R 10 )] m —R 8 —[C(R 10 )] n —CH 3 where m+n is 6 to 10, —[C(R 10 )] 2 —C(R 9 )═C(R 9 )—[C(R 10 )] q —R 8 —[C(R 10 )] r —CH 3 where q+r is 4 to 8 and —C(R 9 )═C(R 9 )—C(R 9 )═C(R 9 )—[C(R 10 )] u —R 8 —[C(R 10 )] v —CH 3 where u+v is 4 to 8;
each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocycylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkynyl;
each R 8 is selected from the group consisting of a direct bond, an optionally substituted arylene and an optionally substituted heteroarylene;
each R 9 is independently hydrogen or alkyl;
each R 10 is independently selected from the group consisting of hydrogen, halo, haloalkyl, alkyl, alkenyl, alkynyl, —R 11 —OR 6 , —R 11 —OC(O)R 6 , R 11 —S(O) p R 6 (where p is 0, 1 or 2), —R 11 C(O)R 6 , —R 11 C(O)OR 6 , —R 11 —N(R 6 )R 7 , and —R 11 —C(O)N(R 6 )R 7 ; and
each R 11 is independently selected from a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; where the compound of formula (I) is not
as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein the compound of formula (I) is selected from the group consisting of:
as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 wherein the compound of formula (I) is a compound of formula (I-1):
as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 wherein the cancer is associated with activation of AKT.
5. The method of claim 3 wherein the cancer is associated with activation of PI 3 kinase.
6. The method of claim 3 wherein the cancer is associated with a deficiency of PTEN activity.
7. The method of claim 3 wherein the cancer is associated with activation of the Wnt signaling pathway.
8. The method of claim 1 wherein the compound is administered orally.
9. The method of claim 3 wherein the compound alters the activity of a component of the AKT/PI 3 kinase signaling pathway.
10. The method of claim 3 wherein the compound inhibits the activity of AKT.
11. The method of claim 10 wherein the compound inhibits the cytosolic to membrane translocation of AKT.
12. The method of claim 3 wherein the compound activates the PTEN phosphatase.
13. The method of claim 1 further comprising administering to the mammal a therapeutically effective amount of an mTOR inhibitor, rapamycin or a PI 3 K inhibitor.
14. The method of claim 13 wherein the PI 3 K inhibitor is selected from the group consisting of wortmannin and LY294002.